TwinBeech Capital’s Neurocrine Biosciences NBIX Stock Holding History

TwinBeech Capital’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-3,110	Closed	-$441K	–	741
2025 Q4	$441K	Buy	+3,110	New	+$451K	0.03%	420
2024 Q4	–	Sell	-182,147	Closed	-$21M	–	826
2024 Q3	$21M	Buy	182,147 +130,947	+256%	+$18M	0.4%	66
2024 Q2	$7.05M	Buy	51,200 +24,348	+91%	+$3.34M	0.14%	179
2024 Q1	$3.7M	Buy	+26,852	New	+$3.67M	0.08%	254
2023 Q4	–	Sell	-81,340	Closed	-$9.15M	–	817
2023 Q3	$9.15M	Buy	81,340 +76,406	+1,549%	+$8.05M	0.18%	159
2023 Q2	$465K	Sell	4,934 -15,905	-76%	-$1.55M	0.01%	513
2023 Q1	$2.11M	Buy	20,839 +12,229	+142%	+$1.27M	0.04%	369
2022 Q4	$1.03M	Buy	+8,610	New	+$1.01M	0.02%	511
2021 Q4	–	Sell	-11,544	Closed	-$1.11M	–	729
2021 Q3	$1.11M	Sell	11,544 -674	-6%	-$63.7K	0.08%	312
2021 Q2	$1.19M	Buy	+12,218	New	+$1.17M	0.14%	195
2020 Q1	–	Sell	-9,526	Closed	-$1.02M	–	413
2019 Q4	$1.02M	Buy	+9,526	New	+$997K	0.3%	113

Other funds holding NBIX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

TwinBeech Capital's NBIX Position: Q1 2026 in Review

TwinBeech Capital sold out of Neurocrine Biosciences (NBIX) in Q1 2026, closing a stake of 3,110 shares — an estimated $441K sold.

TwinBeech Capital first reported a position in NBIX in Q4 2019 and held it in 11 quarters. The position peaked at $21M in Q3 2024. 694 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

TwinBeech Capital reported no remaining Neurocrine Biosciences position as of Q1 2026 after selling out during the quarter.
TwinBeech Capital sold 3,110 Neurocrine Biosciences shares in Q1 2026, an estimated $441K.
TwinBeech Capital first reported a position in Neurocrine Biosciences in Q4 2019 and held it in 11 quarters.
TwinBeech Capital's Neurocrine Biosciences position peaked at $21M in Q3 2024.
694 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on TwinBeech Capital's 13F filing for Q1 2026, filed 15 May 2026.